STOCKHOLM - April 30, 2025 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, continued to deliver sales growth and positive margins in Sweden, alongside steady progress in its UK expansion.

"We remain fully focused on growth in Sweden, our UK establishment, and further development of our system for gastrointestinal diagnostics," says CEO Fredrik Palm, CEO of Inify Laboratories.

Sales in the first quarter amounted to SEK 5.1 million (2.2), representing 130% growth compared to the same period in 2024. Cash balance at the end of the quarter amounted to SEK 151.1 million, strengthened by the SEK 150 million share issue completed in February.

"Our laboratory operations continue to generate positive financial results, with further improvement expected as sample volumes grow," says Palm.

During the first quarter, Inify established its initial UK organisation by recruiting key personnel for subsidiary management, laboratory operations, and sales. Planning for the laboratory construction is progressing well, and the company has selecting a modern, newly built property in a business park just south of Oxford.

"In parallel with the laboratory establishment, we have an ongoing, close dialogue with public (NHS) and private healthcare providers - our future customers," said Palm.

Together with its customers, Inify has begun developing new, structured processes in prostate cancer diagnostics, delivering superior efficiency and quality.

"We are one quarter into what promises to be a very exciting year. Inify is growing in Sweden, expanding internationally, and at the same time developing new capabilities to broaden our service offering into gastrointestinal diagnostics. In short, we are at the forefront of setting a new standard," Palm concludes.

For further information, please contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com 

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardised and AI-supported workflow to optimise quality and response times, initially within prostate cancer. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. Its shares are listed on Euronext Growth Oslo under the ticker INIFY.